vimarsana.com

Page 95 - அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting

Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting Share Article Posters further expand on preclinical immuno-oncology mechanism of action and combination therapy with various checkpoint inhibitors and confirm DRP-104 single agent activity in KEAP1 and STK11 mutant lung tumors and head and neck squamous cell carcinoma New York, NY (PRWEB) April 05, 2021 Dracen Pharmaceuticals, Inc., announced today that three posters profiling its clinical stage glutamine antagonist, DRP-104 (sirpiglenastat), will be presented Saturday, April 10 - Monday, June 21 during the American Association for Cancer Research (AACR) Virtual Annual Meeting. “As our lead asset DRP-104 (sirpiglenastat) advances in phase I clinical development, our preclinical data continues to confirm its promising profile both as a single agent and in combination therapy,” said Robert Wild, Ph.D., chief scientific off

Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

Share this article SAN DIEGO and CALGARY, AB, April 5, 2021 /CNW/ Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors. The webinar will take place on Monday, April 12, 2021 at 2:00 pm ET. The webinar will feature presentations by Key Opinion Leaders Aleix Prat, M.D., Ph.D. (Clínic Barcelona) and Richard Vile, Ph.D., (Mayo Clinic). Dr. Prat s portion of the presentation will focus on data from the AWARE-1 window-of-opportunity clinical trial evaluating pelareorep with and without atezolizumab (Tecentriq

Oncolytics Biotech to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

Oncolytics Biotech to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New software package employs deep-learning algorithms to analyze T-cell receptor sequencing data

New software package employs deep-learning algorithms to analyze T-cell receptor sequencing data Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center have developed DeepTCR, a software package that employs deep-learning algorithms to analyze T-cell receptor (TCR) sequencing data. T-cell receptors are found on the surface of immune T cells. These receptors bind to certain antigens, or proteins, found on abnormal cells, such as cancer cells and cells infected with a virus or bacteria, to guide the T cells to attack and destroy the affected cells. DeepTCR is an open-source software that can be used to answer questions in research into infectious disease, cancer immunology and autoimmune disease; any place where the immune system has a role through its T-cell receptors, said lead study author John-William Sidhom, an M.D./Ph.D. student at the Johns Hopkins University School of Medicine and Department of Biomedical Engineering

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.